2023.12.17 Lucence Early Cancer Screening

Meheal is proud to announce its collaboration with Lucence Early Cancer Screening (超早期癌症篩查). Our commitment to the belief that prevention is the best form of treatment underscores our dedication to partnering with forward-thinking companies. We strongly support initiatives that empower individuals to proactively address health concerns, with a particular focus on cancer, a paramount global health issue.

By joining forces with Lucence Early Cancer Screening, we aim to contribute to the advancement of preventative healthcare solutions. Our shared vision is to enable people to mitigate health risks and enhance overall well-being. Meheal recognises the critical importance of addressing cancer at its early stages, and through this collaboration, we aspire to make significant strides in promoting proactive health management.

Meheal is optimistic that the collaboration with Lucence Early Cancer Screening will have a meaningful impact on a broad spectrum of individuals. Through the provision of this service, we aspire to contribute significantly to public health by offering a valuable resource for early cancer detection and prevention. Our commitment is grounded in the belief that accessible and proactive healthcare solutions can positively influence the lives of many.

So how does this work, LucenceINSIGHT™ is an advanced multi-cancer early detection tool designed to screen for up to 10 cancers through a simple blood draw. It looks for changes in DNA from cancer cells floating in the blood and uses smart analysis to predict site of origin.  The report it gives highlights any areas that might be concerning, helping healthcare providers decide if more evaluation is needed. To gain further insights into Lucence Early Cancer, I recommend exploring their official website for comprehensive information and details https://insight.lucence.com/

To book this service, which includes drawing blood sample, please contact Karen @Meheal on (+852) 3611-1924.